Impact of immune ‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
ConclusionsThe results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Tadashi Nishimura,
Hajime Fujimoto,
Takumi Fujiwara,
Kentaro Ito,
Atsushi Fujiwara,
Hisamichi Yuda,
Hidetoshi Itani,
Masahiro Naito,
Shuji Kodama,
Kazuki Furuhashi,
Akihiko Yagi,
Haruko Saiki,
Taro Yasuma,
Tomohito Okano,
Atsushi Tomaru,
Mo Tags: RESEARCH ARTICLE Source Type: research
Off ‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
ConclusionsAt our institution, ICI was most commonly prescribed in the relapsed/refractory setting to patients with metastatic disease. The treatment was generally well-tolerated in the pediatric population. The overall response rate was low, and the majority of patients eventually experienced disease progression. A few patients, however, had durable treatment responses. Further studies are needed to identify which pediatric patients are most likely to benefit from ICI. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Ajami Gikandi,
Susan N. Chi,
Kee Kiat Yeo,
Allison F. O'Neill,
David S. Shulman,
Steven G. DuBois,
Natalie B. Collins Tags: RESEARCH ARTICLE Source Type: research
Outcomes of the transformation of follicular lymphoma to diffuse large B ‐cell lymphoma in the rituximab era: A population‐based study
ConclusionThe outcome of t-DLBCL in the rituximab era was better than historical series before the rituximab era. Due to the good prognosis, we did not recommend autologous stem cell transplantation for t-DLBCL receiving watch-and-wait or radiation as initial therapy before HT. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Wenshuai Zheng,
Mingjuan Liu,
Lixun Guan,
Shenyu Wang Tags: RESEARCH ARTICLE Source Type: research
Identifying predictors of COVID ‐related delays in cancer‐specific medical care
ConclusionThese findings may inform cancer care delivery during periods of instability when treatment may be disrupted by informing clinicians about concerns that patients have during the treatment process. Future research should assess whether delays in cancer care impact long-term cancer outcomes and whether delays exacerbate existing disparities in cancer outcomes. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Breanna B. Greteman,
Natalie J. Del Vecchio,
Crystal J. Garcia‐Auguste,
Amanda R. Kahl,
Brian M. Gryzlak,
Elizabeth A. Chrischilles,
Mary E. Charlton,
Sarah H. Nash Tags: RESEARCH ARTICLE Source Type: research
Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial
This study was conducted to compare the clinical outcome of surufatinib combined with TAE versus surufatinib monotherapy in liver metastatic NETs.MethodsThis is a prospective, multicenter, open-label, and randomized controlled trial. Patients diagnosed with liver metastatic NETs will be enrolled. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the control group. Patients will be treated with surufatinib plus TAE in the experimental group, while patients in the control group will receive surufatinib monotherapy. The primary endpoint is progression-free survival (PFS) assessed by a blind...
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Ruizhen Li,
Xiaofen Li,
Xin You,
Minggang Su,
Yuzhi Liu,
Nengwen Ke,
Dan Cao Tags: RESEARCH ARTICLE Source Type: research
Correction to “Are embryonic stem cell markers and ALDH1A1 relevant in the context of breast cancer estrogen positivity”
(Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Tags: CORRECTION Source Type: research
Issue Information
(Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Real ‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
ConclusionThis study revealed the heterogeneity of treatment patterns and survival outcomes in patients with stage III NSCLC before durvalumab consolidation came into clinical practice. There is an unmet need for patients who are not eligible for surgery as an initial therapy. Novel therapeutic approaches are highly warranted to improve clinical outcomes. (Source: Cancer Medicine)
Source: Cancer Medicine - April 16, 2024 Category: Cancer & Oncology Authors: Jiyun Lee,
Hee Kyung Ahn,
Sang ‐We Kim,
Ji‐Youn Han,
Sung Sook Lee,
Hyung Soon Park,
Hyun Woo Lee,
Joo‐Hang Kim,
Eunhan Cho,
Reto Huggenberger,
Byoung Chul Cho Tags: RESEARCH ARTICLE Source Type: research
Clinical laboratory characteristics and gene mutation spectrum of Ph ‐negative MPN patients with atypical variants of JAK2, MPL, or CALR
ConclusionThese data indicate that classical mutations ofJAK2,MPL, andCALR may not be completely mutually exclusive with atypical variants ofJAK2,MPL, andCALR. In this study, 30 different atypical variants ofJAK2,MPL, andCALR were identified,JAK2 G127D being the most common (42%, 23/55). Interestingly,JAK2 G127D only co-occurred withJAK2V617F mutation. The incidence of atypical variants ofJAK2 inPh-negative MPNs was much higher than that of the atypical variants ofMPL andCALR. The significance of these atypical variants will be further studied in the future. (Source: Cancer Medicine)
Source: Cancer Medicine - April 15, 2024 Category: Cancer & Oncology Authors: Zhanlong Wang,
Xin Tian,
Jinyu Ma,
Yuhui Zhang,
Wenru Ta,
Yifan Duan,
Fengli Li,
Hong Zhang,
Long Chen,
Shaobin Yang,
Enbin Liu,
Yani Lin,
Weiping Yuan,
Kun Ru,
Jie Bai Tags: RESEARCH ARTICLE Source Type: research
The RNA ‐binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA
ConclusionsThe discernments delineate RBMS3 as a novel suppressor of cancer via LIMS1, thereby bestowing fresh therapeutic possibilities and illuminating the intricacies of colon cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - April 15, 2024 Category: Cancer & Oncology Authors: Yafei Li,
Shuoshuo Wang,
Guoli Li,
Chunyang Gao,
Zihan Cui,
Mingqi Cong,
Jie Hu,
Minghui Zhang,
Xiaoming Jin,
Haiying Sun,
Dan Kong Tags: RESEARCH ARTICLE Source Type: research
Expression and prognostic significance of the PD ‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma
ConclusionsThese data emphasize the importance of PD-1-mediated immune evasion in the complex landscape of immune oncology in AR-NHL co-infected with EBV, and contribute to the diagnostic classification and possible definition of immunotherapeutic strategies for this unique subgroup. (Source: Cancer Medicine)
Source: Cancer Medicine - April 13, 2024 Category: Cancer & Oncology Authors: Han Zhao,
Shaohang Cai,
Yanhua Xiao,
Muye Xia,
Hongjie Chen,
Zhiman Xie,
Xiaoping Tang,
Haolan He,
Jie Peng,
Juanjuan Chen Tags: RESEARCH ARTICLE Source Type: research
PD ‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
ConclusionOur results indicated that WBRT combined with immunotherapy improved survival in SCLC-BMs patients compared to WBRT monotherapy. Administering WBRT prior to ICI treatment is associated with improved survival outcomes compared to WBRT following ICI treatment, for patients with SCLC-BMs. These findings highlight the significance of conducting further prospective researches on combination strategies of intracranial radiotherapy and ICI in SCLC-BMs patients. (Source: Cancer Medicine)
Source: Cancer Medicine - April 13, 2024 Category: Cancer & Oncology Authors: Litang Huang,
Shen Chen,
Hui Liu,
Lu Meng,
Chengxing Liu,
Xiaoting Wu,
Yingying Wang,
Shilan Luo,
Hongbin Tu,
Chunlei Wang,
Ming Zhang,
Xiaomei Gong Tags: RESEARCH ARTICLE Source Type: research
Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma
ConclusionsThis study successfully established a precise predictive model for OCCC patient metastasis using machine learning techniques, offering valuable support to clinicians in making informed clinical decisions. (Source: Cancer Medicine)
Source: Cancer Medicine - April 13, 2024 Category: Cancer & Oncology Authors: Qin ‐Hua Guo,
Feng‐Chun Xie,
Fang‐Min Zhong,
Wen Wen,
Xue‐Ru Zhang,
Xia‐Jing Yu,
Xin‐Lu Wang,
Bo Huang,
Li‐Ping Li,
Xiao‐Zhong Wang Tags: RESEARCH ARTICLE Source Type: research
The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression
ConclusionThe m6A methyltransferase METTL5 is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis. METTL5 accelerates malignant progression of HCC by promoting generation and release of the neutrophil extracellular traps (NETs) network, providing new insights for clinical biomarkers and immunotherapeutic targets in HCC prognosis. (Source: Cancer Medicine)
Source: Cancer Medicine - April 13, 2024 Category: Cancer & Oncology Authors: Qi Wang,
Yuxi Huang,
Yu Zhu,
Wenlong Zhang,
Binfeng Wang,
Xuefeng Du,
Qiqiang Dai,
Fabiao Zhang,
Zheping Fang Tags: RESEARCH ARTICLE Source Type: research
Outcomes after fertility ‐sparing surgery of early‐stage ovarian cancer: A nationwide population‐based study
ConclusionFSS can be a safe alternative procedure in selected young patients of Stage I EOC who have fertility desire. Endometrial biopsy before or during FSS and regular surveillance to detect recurrence are mandatory for ovarian cancer patients undergoing FSS. (Source: Cancer Medicine)
Source: Cancer Medicine - April 12, 2024 Category: Cancer & Oncology Authors: Chia ‐Yi Lee,
Chun‐Ju Chiang,
Yi‐Jou Tai,
Heng‐Cheng Hsu,
Yu‐Li Chen,
Ying‐Cheng Chiang,
Chia‐Ying Wu,
Wen‐Chung Lee,
Hsiao‐Lin Hwa,
Wen‐Fang Cheng Tags: RESEARCH ARTICLE Source Type: research
